Idexx Laboratories (IDXX) stock
Health Care · Health Care Equipment
Idexx Laboratories (IDXX) is a Health Care Equipment company in the Health Care sector, headquartered in Westbrook, Maine. As of October 23, 2026, IDXX closed at $560.38, a market capitalization of $44.15 billion, the 256th largest company in the S&P 500. Over the last twelve months it generated $4.55 billion in revenue (+10% year over year) and $1.24 billion in free cash flow. The stock trades at 39.4x trailing earnings and 33.5x forward earnings.
- 1-year total return: -12.2% (dividends reinvested)
- 5-year return: -3.0% a year
- 52-week range: $500.61 – $769.98
- Gross margin 62.4%, operating margin 35.0%
- FI Handbook report card: B- across 10 metrics
- 34th largest of 60 Health Care stocks in the S&P 500
IDXX price chart
1Y price change: -12.2% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| IDXX | +7.3% | -17.2% | -12.2% | +9.4% | -3.0% | +17.6% | +19.8% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 1991.
IDXX key statistics
- Market cap
- $44.1B
- #256 in S&P 500
- P/E (TTM)
- 39.4x
- Forward P/E
- 33.5x
- EPS (TTM)
- $14.23
- Revenue (TTM)
- $4.6B
- +10%
- Free cash flow
- $1.2B
- Gross margin
- 62.4%
- Operating margin
- 35.0%
- Return on equity
- 74.2%
- Dividend yield
- None
- 52-week range
- $500.61 – $769.98
- Beta
- 1.55
- Price / sales
- 9.7x
- EV / EBITDA
- 27.8x
- Debt / equity
- 0.68x
- Employees
- 11,000
IDXX report card
B-Ten fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth9.7%C
- Gross margin62.4%A
- Operating margin35.0%A
- FCF margin27.2%A
- Return on equity74.2%A
- Net debt / EBITDA0.6xB
- Forward P/E33.5xD
- PEG ratio2.9xD
- Shareholder yield2.8%C
- Share count change / yr-1.3%B
IDEXX Laboratories financials
Revenue went from $1.8B in fiscal 2016 to $4.3B in fiscal 2025, growing 10.3% a year.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8B | $2.0B | $2.2B | $2.4B | $2.7B | $3.2B | $3.4B | $3.7B | $3.9B | $4.3B |
| Gross profit | $975.4M | $1.1B | $1.2B | $1.4B | $1.6B | $1.9B | $2.0B | $2.2B | $2.4B | $2.7B |
| Operating income | $350.2M | $413.0M | $491.3M | $552.8M | $694.5M | $932.0M | $898.8M | $1.1B | $1.1B | $1.4B |
| Net income | $222.0M | $263.1M | $377.0M | $427.7M | $581.8M | $744.8M | $679.1M | $845.0M | $887.9M | $1.1B |
| EPS (diluted) | $2.44 | $2.94 | $4.26 | $4.89 | $6.71 | $8.60 | $8.03 | $10.06 | $10.67 | $13.08 |
| Free cash flow | — | $298.9M | $284.3M | $304.2M | $541.1M | $636.0M | $394.1M | $772.9M | $808.1M | $1.1B |
| Buybacks | $304.1M | $282.6M | $369.3M | $301.7M | $182.8M | $746.8M | $819.7M | $71.9M | $837.0M | $1.2B |
| Diluted shares | 90.9M | 89.6M | 88.5M | 87.5M | 86.7M | 86.6M | 84.6M | 84.0M | 83.2M | 81.0M |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into IDXX?
A reverse DCF asks what growth the current price requires. With an enterprise value of $45.0B and $1.2B of trailing free cash flow, IDEXX Laboratories needs to grow free cash flow about 26.0% a year for ten years (fading to 3.0% terminal growth) to earn a 10% annual return. For context, free cash flow grew 14.3% a year over the last five years.
P/E ratio history
Current 42.8x vs. median 45.4x (10th–90th percentile 29.9x–76.7x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
IDXX analyst price targets
12 analysts' average 12-month target is $698.00 (+25% vs. $560.38). Targets range from $470.00 to $805.00. 64% rate it a buy.
IDXX earnings
Next report: November 2, 2026. IDEXX Laboratories has beaten EPS estimates 8 quarters in a row. Last quarter's revenue was $1.2B (+10% year over year).
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Aug 4, 2026 | $3.93 | $4.27 | +8.5% |
| May 5, 2026 | $3.41 | $3.47 | +1.7% |
| Feb 2, 2026 | $2.94 | $3.08 | +4.8% |
| Nov 3, 2025 | $3.15 | $3.40 | +8.1% |
| Aug 4, 2025 | $3.30 | $3.63 | +10.0% |
| May 1, 2025 | $2.84 | $2.96 | +4.1% |
| Feb 3, 2025 | $2.40 | $2.62 | +9.2% |
| Oct 31, 2024 | $2.69 | $2.80 | +4.3% |
Stocks like IDXX
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 ABT Abbott Laboratories | +1.16% | -16% | $179.4B | 38.6x | Compare |
 ISRG Intuitive Surgical | +1.90% | -18% | $159.8B | 54.7x | Compare |
 MDT Medtronic plc. | -1.22% | +5% | $122.0B | 23.4x | Compare |
 SYK Stryker | +0.02% | -19% | $117.8B | 31.8x | Compare |
 BSX Boston Scientific | -0.70% | -55% | $66.2B | 18.5x | Compare |
 BDX Becton, Dickinson and | -0.75% | +39% | $54.2B | 46.3x | Compare |
 EW Edwards Lifesciences Corporatio | -1.13% | +16% | $51.3B | 53.0x | Compare |
 RMD ResMed | -0.08% | -4% | $35.6B | 24.2x | Compare |
IDXX news
- Here's How IDEXX Laboratories Is Placed Ahead of Q3 Earnings · Oct 23, 2026
- IDEXX Laboratories (IDXX) vs. ZTS and NEOG: Can Raised Guidance and Product Expansion Drive Further Earnings Growth? · Oct 22, 2026
- IDEXX Laboratories (IDXX) Rebounds On Jefferies Support, Is It Still 20% Undervalued? · Oct 21, 2026
- Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report? · Oct 20, 2026
- Idexx (IDXX) Moves to Buy: Rationale Behind the Upgrade · Oct 19, 2026
IDXX stock FAQ
What is IDXX's market cap?
Idexx Laboratories's market capitalization is $44.15 billion as of October 23, 2026, ranking 256th in the S&P 500.
What is IDXX's P/E ratio?
IDXX trades at a trailing price-to-earnings ratio of 39.4x and a forward P/E of 33.5x. Its median P/E over the period we track is 45.4x.
Does IDXX pay a dividend?
No. Idexx Laboratories does not currently pay a regular cash dividend.
How much has IDXX stock returned?
Including reinvested dividends, IDXX returned -12.2% over one year, -3.0% a year over five years, +17.6% a year over ten years through October 23, 2026.
Is IDXX stock overvalued?
At today's price, a reverse discounted cash flow model (10% discount rate, 3% terminal growth) implies Idexx Laboratories must grow free cash flow about 26% a year for the next decade. Its free cash flow grew 14% a year over the last five years. Whether that is achievable decides if the stock is cheap or expensive. This is a model, not advice.
What is the IDXX price target?
12 analysts cover IDXX with an average 12-month price target of $698.00, +25% from the current price. 64% of them rate it a buy.
When does IDXX report earnings?
Idexx Laboratories is expected to report earnings on November 2, 2026. It has beaten EPS estimates 8 quarters in a row.
How many employees does Idexx Laboratories have?
Idexx Laboratories has about 11,000 full-time employees, or $413,929 of revenue per employee.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology